

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 13/00, C12N 15/51 A61K 39/29, G01N 33/576 A61K 39/395	A1	(11) International Publication Number: WO 91/14703 (43) International Publication Date: 3 October 1991 (03.10.91)
(21) International Application Number: PCT/GB91/00444 (22) International Filing Date: 25 March 1991 (25.03.91) (30) Priority data: 9007024.4 29 March 1990 (29.03.90) GB (71) Applicant (for all designated States except US): IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE [GB/GB]; University of London, London SW7 2AZ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : THOMAS, Howard, Christopher [GB/GB]; The Department of Medicine, Queen Elizabeth The Queen Mother Wing, St. Mary's Hospital Medical School, London W2 1PG (GB). CARMAN, William, Frederick [GB/GB]; The Institute of Virology, Church Street, Glasgow G11 5JR (GB).		(74) Agents: TYRRELL, Arthur, William, Russell et al.; Smith-Kline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HEPATITIS B VACCINE (57) Abstract A variant HBsAg protein of fragment thereof displaying the antigenicity of Hepatitis B virus surface antigen is disclosed, in which the variant protein or fragment thereof (vHBsAg) comprises a modified 'a' determinant in which there is an amino acid other than glycine at position 145 of the HBsAg sequence. A vaccine comprising the vHBsAg is provided, as is a kit for diagnostic <i>in vitro</i> detection of anti-vHBsAg antibodies and an antibody preparation comprising anti-vHBsAg antibodies.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

-1-

Hepatitis B vaccine

This invention relates to recombinant DNA molecules that code for polypeptides with the specificity of a hepatitis B viral antigen.

More particularly this invention relates to a vaccine composition for stimulating the production of antibodies in humans to a variant hepatitis B virus.

10

Infection with hepatitis B virus (HBV) is a serious, widespread problem but vaccines which can be used for mass immunisation are now available, for example the product 'Engerix-B' (SmithKline Beecham p.l.c.) which is obtained by genetic engineering techniques.

The cloning of genomes of Hepatitis B virions of different serotypes is well known in the art; see Miller et al., Hepatology, 9 (1989) page 322 and references therein. Dane particles which are hepatitis B virions and which are isolatable from infected patients have a diameter of about 42nm. Each consists of an envelope comprising the hepatitis B surface antigen (HBsAg), a capsid (HBcAg), an endogenous polymerase and a DNA genome. A third polypeptide, 'e' antigen (HBeAg) is made by hepatitis B virus and found in solubilized form in serum.

Commercially available vaccines against HBV comprise Hepatitis B virus surface antigen (HBsAg) either in native or recombinant form. The authentic Hepatitis B virus surface antigen can be recovered from plasma of infected individuals as a particle of about 22nm comprised of two proteins known as P24 and its glycosylated derivative GP28, both of which are encoded by the 226 amino acid coding sequence on the HBV genome known as the S protein coding sequence or HBV S-gene; see Tiollais et al., Nature, 317 (1985), page 489 and references therein. The complete amino

-2-

acid sequence of, and nucleotide sequence encoding, HBsAg is given in Valenzuela et al, Nature, 280 (1979), page 815. The numbering system used by Tiollais et al. (loc cit.) to define nucleotide and amino acid positions is used herein.

5

Insertion of HBV S-gene coding sequences under the control of yeast promoters on expression vectors to enable expression of HBsAg in S. cerevisiae for vaccine production has been described by, for example, Harford et al in Develop. Biol. Standard. 54: page 125 (1983), Valenzuela et al., Nature 298, page 347 (1982) and Bitter et al., J. Med. Virol. 25, page 123 (1988). Expression in Pichia pastoris has also been described by Gregg et al, Biotechnology, 5 (1987), page 479 (see also European Patent Application Publication No. 0 226 846) as has expression in Hansenula polymorpha (see EP-A- 0 299 108).

Vaccines may also be prepared from hybrid immunogenic particles comprising HBsAg protein as described in European Patent Application Publication No. 0 278 940.

Such particles can contain, for example, all or part or parts of the HBsAg precursor protein encoded by the coding sequence which immediately precedes the HBV-S gene on the HBV genome, referred to herein as the Pre S coding sequence. The Pre S coding sequence normally codes for 163 amino acids (in the case of the ay HBV sub type) and comprises a Pre S1 coding sequence and a Pre S2 coding sequence. The latter codes for 55 amino acids and immediately precedes the S protein coding sequence (see EP-A-0 278 940 for further details).

Antigenic subtypes of HBV are defined serologically and have been shown to be due to single base changes in the region of the genome encoding HBsAg (Okamoto et al., J. Virol., 1987,

-3-

74, 5463-5467). However, all known antigenic subtypes contain the 'a' determinant consisting of amino acids 124 to 147 of HBsAg. Antibody to the 'a' determinant confers protection against all subtypes. It has been shown by in vitro mutagenesis that the cysteine at position 147 and the proline at position 142 are important for the exhibition of full antigenicity of the 'a' determinant (Ashton et al, J. Med. Virol., 1989, 29, page 196).

10 During the last decade, several putative variants of hepatitis B virus (HBV) have been described.

Mc Mahon et al have reported that substitution of arginine for glycine in the putative monoclonal antibody binding domain of HBsAg was found (as deduced by DNA sequence analysis) in a liver transplant patient treated with anti-HBsAg monoclonal antibody (Cold Spring Harbor Symposium on the Molecular Biology of Hepatitis B viruses, September, 1989). This result does not however provide any incentive to synthesise a variant HBsAg amino acid sequence or develop a vaccine composition based thereon.

In another report, children and adults were found with circulating hepatitis B surface antigen, indicating viral replication, despite the presence of specific antibody (anti-HBs) after immunisation with one of two licensed hepatitis B vaccines (Zanetti et al, Lancet, November 1988, page 1132). Analysis of the HBsAg with monoclonal antibodies revealed that the circulating antigen did not carry the 'a' determinant or that this determinant was masked. It was concluded that emergence of a variant of hepatitis B virus had been detected, possibly due to epidemiological pressure associated with immunisation in an endemic area of infection. The variant was, however, not characterised further.

-4-

From the work of Zanetti et al. it is clear that a potential disadvantage with presently available hepatitis B vaccines is that they may, at least in a host with a predisposing immunogenetic make-up, cause the appearance of an 'escape mutant', i.e. a replicating infectious virus that has mutated away from neutralising immunity. Such a variant virus clearly has the capacity to cause disease and may be assumed to be transmissible. The variant virus may therefore give rise to a serious immunisation problem since it is not effectively neutralised by antibodies produced by vaccines based on normal HBsAg.

The present invention overcomes, or at least mitigates, the above disadvantages associated with known HBV vaccines.

15

According to the present invention there is provided an HBsAg protein or a fragment thereof displaying the antigenicity of HBV surface antigen, characterised in that the protein or fragment thereof comprises a modified 'a' determinant in which there is an amino acid other than glycine at position 145 of the HBsAg sequence.

It is to be understood that the variant HBsAg may also include Pre S sequences if so desired.

25

The variant HBsAg protein or fragment thereof according to the invention is hereinafter abbreviated to vHBsAg.

It will be appreciated that the vHBsAg is not in a 'naturally occurring' form but is synthetic or highly purified material, free of blood products.

Preferably the vHBsAg of the invention corresponds to full length HBsAg and is identical to normal HBsAg except for the altered amino acid residue at position 145.

-5-

Preferably the vHBsAg is in highly purified form, for example in a state of purity greater than 75%, more preferably greater than 90%, and most preferably is 95-100% pure.

In a further aspect of the present invention there is provided a vaccine composition comprising an immunoprotective amount of the vHBsAg together with a suitable carrier.

Other aspects of the invention are described hereinbelow.

The vHBsAg and vaccine of the invention may be used to overcome the problems perceived by the emergence of an 'escape mutant' as defined hereinabove in which the 'a' determinant of the viral HBsAg has undergone modification. In particular the vaccine of the invention has the advantage that it may be used to protect against, and prevent the emergence or transmission of, a variant HBV which is defined herein as having a modified 'a' determinant in the HBsAg amino acid sequence wherein there is an amino acid other than glycine at position 145.

Accordingly there is also provided a method for protecting a human against disease symptoms associated with infection with said variant HBV, which method comprises administering to the human a safe and effective amount of the vaccine according to the invention.

30

In another aspect the present invention provides vHBsAg for use in therapy, especially prophylaxis.

The invention also provides the use of vHBsAg in the manufacture of a vaccine composition for protecting a human against disease symptoms associated with said variant HBV

-6-

infection.

When used to immunise humans against an existing variant HBV virus it will be appreciated that the vHBsAg sequence in the vaccine will normally match, or be antigenically equivalent to, the vHBsAg sequence in the variant HBV virus.

Preferably the amino acid at position 145 in the vHBsAg of the invention is such that it may be derived by a point mutation in the GGA codon coding for glycine at position 145 in normal HBsAg.

In a preferred embodiment of the invention the glycine residue at position 145 of normal HBsAg is replaced by a more hydrophilic amino acid since this results in enhanced antigenicity.

In a particularly preferred embodiment of the invention the modification at position 145 in the 'a' determinant of HBsAg is substitution of glycine by arginine, since, as described hereinbelow, this modification has been shown to arise on an HBV variant isolated clinically.

In order to describe the invention more clearly, reference is made to the following figures, in which:

Figure 1 shows a schematic view of a part of the normal HBsAg amino acid sequence indicating the two loops of the 'a' determinant and the glycine residue at position 145;

30

Figure 2 shows a schematic view of the nucleotide sequence of a clinically isolated variant HBsAg, indicating primer binding sites used for PCR and sequencing and the AGA codon found at positions 587-589 resulting from a G to A point mutation at position 587 in the normal sequence;

35

-7-

Figure 3 shows a diagrammatic representation of the S-gene on plasmid pRIT10601 or pRIT 13438 indicating oligonucleotide binding sites for the polymerase chain reaction (PCR);

5

Figure 4 shows a diagrammatic representation of the plasmid pRIT13438;

Figure 5 shows a diagrammatic representation of the plasmid pNN2deltaEco RI; and

Figure 6 shows a diagrammatic representation of the plasmid pRIT12775. Polylinker 1 is as follows:

0.01/BglIII.ClaI.HindIII.BamHI.AvaI.SmaI.AvaI.XhoI.SalI.

15

In a further aspect of the invention there is provided a process for preparing the vHBsAg and the vaccine composition obtained therefrom.

20 Preferably the vHBsAg is obtained synthetically, either by peptide synthesis or more preferably by recombinant DNA techniques.

Methods for the construction, manipulation and verification of recombinant DNA molecules and sequences are well known in the art. To change glycine into a different amino acid at position 145 of the normal HBV S protein of HBsAg (see Figure 1) to obtain the vHBsAg of the invention it is required to change the codon GGA at positions 433-435 of the S-gene nucleotide sequence to a different codon encoding the required amino acid.

In a particular embodiment it is preferable to change the GGA codon to, most preferably, AGA or less preferably to CGA or CGC or CGG or CGT or AGG, all of which triplets encode arginine.

-8-

Several methods are available to effect the appropriate change of sequence. One suitable method is complete de novo synthesis, by phosphite or phosphoramidite chemistry, of the desired coding sequence using viral or yeast codon
5 frequencies.

Synthesis of DNA is available from several companies on a commercial basis. An example of such gene synthesis is described by Hayden and Mandecki, DNA 7: p571 (1988) and
10 references therein.

A second method is to clone on a single strand vector an appropriate restriction fragment from a vector which already comprises the HBV genome and thereafter effect site specific
15 in vitro mutagenesis as described by Botstein and Shortle, Science, 229, p. 1193 (1982). A culture of E. coli K12 strain C600 containing the recombinant plasmid pRIT10601 comprising an HBV genome of ay subtype cloned on pBR322 was deposited in accordance with the Budapest Treaty in the
20 American Type Culture Collection on 2nd June, 1982 under Accession Number ATCC 39132. The sequence coding for the S-gene specifying the 226 amino acid HBsAg protein or longer sequences coding for Pre S polypeptides can be excised from such clones by standard recombinant DNA techniques.

25 One appropriate restriction fragment is the 575 bp XbaI - AccI fragment from within the S-gene coding region of pRIT10601. Vector systems useful for in vitro mutagenesis are commercially available. The mutated gene fragment so
30 obtained is reinserted into the S-gene.

A third method is to effect the desired mutational change using polymerase chain reaction (PCR) technology as described by Ho et al, Gene, 77: p51 (1989).

35 In each case the vHBsAg coding sequence may be expressed under the control of a suitable promoter in any suitable

-9-

host.

Expression vectors comprising the DNA sequence encoding vHBsAg are novel and form a further aspect of the present invention. Hosts transformed with the said expression vectors form yet another aspect of the invention.

In a preferred aspect S. cerevisiae, Pichia pastoris or Hansenula polymorpha may be used as the host and expression is under the control of a yeast promoter, such as the yeast TDH3 promoter (glyceraldehyde- 3-phosphate dehydrogenase gene, see Valenzuela et al., 1982; Bitter et al., 1988, supra) or PH05 (Miyanochara et al., Proc. Natl. Acad. Sci. USA 80, p. 1, 1983), MOX, FMDH (see EP-A-0 299 108) and AOX (see EP-A-0 226 846).

The transformed host can be cultured or fermented by conventional means and the vHBsAg extracted and purified. Purification of HBsAg from yeast cells is well known in the art and can be done according to any of US 4,649,192, US 4,683,294, US 4,694,074 or US 4,738,926. Purification of the vHBsAg of the invention is carried out in an analogous manner.

Vaccines containing the vHBsAg are prepared by conventional techniques and will contain an immunoprotective amount of the vHBsAg preferably in buffered physiological saline and admixed or adsorbed with any of the various known adjuvants including aluminium hydroxide and aluminium phosphate. By "immunoprotective" is meant that enough of the vHBsAg is administered to elicit a sufficient protective antibody or cell mediated immune response to confer protection against the infectious agent without serious side effects. The amount of vHBsAg to be administered will depend on whether the vaccine is adjuvanted and will generally comprise between 1 to 1000 mcg of protein, for example 1 to 200 mcg

-10-

protein, more preferably 5 to 40 mcg protein. The amount and number of doses to be administered can be determined in standard dose range studies involving observation of antibody titres and other responses in subjects.

5

The vHBsAg may also be mixed with other HBsAg such as normal HBsAg or homogenous or composite HBsAg particles containing all or part or parts of the PreS1 or PreS2 polypeptides for vaccine formulation. It may also be mixed with hybrid HBsAg
10 particles carrying epitopes from proteins from other organisms and with other immunogens to form bivalent or multivalent vaccines. Vaccine preparation is generally described in "Vaccines", edited by Voller et al, University Park Press, Baltimore, MD, U.S.A., 1978.

15

The vHBsAg is useful for inclusion as an immunological reagent in detection kits for variant HBV virus infection and the like. It can also be used to raise polyclonal and monoclonal antibodies by known methods, some of which
20 monoclonal antibodies may be specific for the variant antigen and not recognise normal HBsAg.

Accordingly in another aspect of the invention there is provided a kit for the diagnostic in vitro detection of anti
25 vHBsAg antibodies in a biological medium, and in particular neutralising antibodies following vaccination, characterised in that it comprises:

- a) vHBsAg as herein defined; and
- 30 b) means adapted to detect the antigen-antibody reaction.

-11-

In a further aspect the invention provides an antibody preparation comprising anti-vHBsAg antibodies for use in the prevention or treatment of hepatitis B infection in humans.

There is also provided a method of treating humans with an
5 effective amount of such anti-vHBsAg antibody to prevent or treat hepatitis B infection.

The invention will now be illustrated by the following examples.

-12-

Example 1Identification of variant Hepatitis B virus ('escape mutant')

5

(a) Methods(i) Immunisation with HBV vaccine

10 A number of trials of HBV vaccine were begun in Italy in 1982. Several centres took part, one of which, the Fourth Division of Infectious Diseases at Hospital D. Cotugno in Naples, followed up 1590 people. The region from which most of these patients came, Campania, has an HBsAg prevalence of
15 greater than 5%. The patients were mostly infants of HBsAg positive carriers, from two regions of southern Italy, who were vaccinated with either HB-VAX (Merck Sharp and Dohme) or HEVAC-B (Pasteur), both plasma-derived vaccines. Doses of 20 ug of the former for adults (10 ug for infants) at 0,
20 1 and 6 months or 5 µg of the latter at 0, 1, 2 and 14 months were given. Babies were also given 0.5 ml hepatitis B hyperimmunoglobulin (HBIG) (Biagini), prepared by the Chon ethanol fractionation procedure, at birth and at 1 month of age. A number of family contacts of carriers, both adults
25 and children, were also vaccinated.

(ii) Hepatitis markers

Blood samples were tested for HBsAg, HBeAg, anti-HBe,
30 anti-HBs and anti-HBc using commercial kits (Abbott Laboratories). Anti-HBs was estimated by comparison with a standard curve generated with a quantitation panel (Abbott Laboratories). HBsAg positivity was confirmed both by retesting and by neutralisation using the HBsAg Confirmatory
35 Assay (Abbott Laboratories). HBsAg neutralisations were

-13-

performed using a serum containing almost exclusively anti-a. Sera from patients with markers of viral replication were also tested for alanine aminotransferase (ALT) levels.

5

(iii) HBsAg and anti-HBs subtyping

Subtyping HBsAg was performed on the carrier contacts of 5 infected babies and 5 infected children, 6 of 8 of the
10 family contacts of infected adults and cases AS, AA and AE as well as 2 of the adult cases. For subtyping, beads coated with anti-a, anti-d, or anti-y (Sorin Biomedica) were incubated overnight at room temperature with serum. After washing with distilled water, 13.2 μCi ^{125}I sheep anti-HBs
15 was added, left for 1 hour at 45°C , washed and quantified in a scintillation counter. A sample was considered ay when the counts obtained using either anti-a or anti-y on the solid phase exceeded 2.1 times the negative control mean value (of 7 healthy HBV negative persons) and that obtained
20 with the anti-d beads was lower than the cut-off value. Samples were considered to have only y reactivity if the counts were higher than the cut-off value when added to anti-y on the solid phase, but lower than the cut-off value when added to anti-a or anti-d solid phases.

25

Specificity of reactivity was confirmed by neutralisation with monoclonal antibodies (Sorin Biomedica). HBsAg positive sera were mixed with monospecific anti-a, anti-d or anti-y antibody before subtyping. A reference
30 HBsAg-containing serum was used as a control.

Anti-HBs subtyping was performed on cases AS, AA and 2 of the adult cases, using a sandwich RIA which employs a recombinant HBsAg (rHBsAg) of one subtype on the solid phase
35 and a radioiodinated one of a different subtype as the probe. Polystyrene beads were coated with either ad or ay

-14-

rHBsAg. To detect anti-a, 0.2 ml of serum was incubated overnight at room temperature with beads. After washing, the beads were incubated with radioiodinated rHBsAg for 2 hours at 40°C. After washing, the radioactivity of the 5 beads was counted. For the ad subtype assay, beads coated with ad were probed with labelled ad rHBsAg and similarly for the ay assay. Specimens with counts above 4 times the mean of the negative control were positive. Titres were expressed as mIU/ml compared to a standard panel. The 10 percentage of anti-a in a serum was determined by calculating the anti-a over anti-ad or anti-ay times 100.

(iv) Patients for sequencing studies

15 An HBsAg, HBeAg and anti-HBc positive carrier (patient IE) with an ALT of 105 was delivered of a male infant (AS) on 5th March, 1983. The father was anti-HBc and anti-HBs positive. At birth and 1 month later, the infant was given 1.5 ml of HBIG and he was vaccinated with HB-VAX (Merck 20 Sharp and Dohme) at 3 months, 4 months and 9 months of age. For sequencing studies, sera were chosen from the mother at delivery, the child at 11 months of age (HBsAg, HBeAg and anti-HBc positive; anti-HBs 420 mIU/ml; ALT 120) and 5 years later (HBsAg and HBeAg positive, anti-HBs negative; ALT 36). 25 Sera from 4 randomly chosen Italian HBeAg positive carriers not involved in the study, and from 3 British HBsAg positive patients were also sequenced.

(v) PCR and direct sequencing

30

50 µl serum was digested in 25 mM sodium acetate, 2.5 mM EDTA, 0.5% SDS and 1 mg/ml proteinase K (Boehringer Mannheim), in a volume of 200 µl overnight at 37°C. After 2 phenol/chloroform and 2 chloroform extractions, the DNA was 35 precipitated with ethanol and the pellet washed with 70%

-15-

ethanol. The pellet was resuspended in 20 μ l of water. PCR was performed on 10 μ l of the DNA with 300 pmol each of primers BCS2 and BCS4 using the method of Carman *et al*, Lancet, 1989, ii, 588-591. Details of the target sequence, primer binding sites and primer sequences are given in Figure 2.

After agarose gel electrophoresis of 10 μ l of the reaction to confirm the presence of amplified DNA, the remainder was spun through a G-50 Sephadex column (Pharmacia) and precipitated with ethanol. After 3 washes with 70% ethanol, the pellet was resuspended in 20 μ l of water. Meanwhile, 10 pmol of sequencing primer BCS3 was endlabelled in a standard buffer with 10 μ Ci gamma³²P-ATP using 10 U polynucleotide kinase (Boehringer Mannheim) in a final volume of 20 μ l. The sequencing primer was not column-purified after labelling.

4 μ l of the DNA was added to 4 μ l of labelled BCS3 in the presence of 2 μ l of 5X buffer, as supplied in the Sequenase kit (United States Biochemicals), heated to 95°C and cooled slowly to 50°C. The manufacturer's recommendations were followed except that the labelling step was omitted and the termination mixes were diluted with an equal volume of water. Reactions were electrophoresed on a 5% Sequagel (National Diagnostics) polyacrylamide-urea gel.

(vi) Hydrophobicity plots

Amino-acids 139 to 147 of the 'a' determinant from the normal and the mutant HBsAg were analysed using Prosis (Pharmacia) software.

-16-

(b) Results(i) Subtyping studies

5 Of the 1590 vaccinees, 44 (2.8%) developed HBsAg, of whom 12 showed weak reactivity and no other HBV markers. Details were obtained on 18 of these patients: 5 infants born to carrier mothers, 5 child family contacts and 8 adult family contacts.

10

The subtype of HBV was determined to be ay in all the contacts of the infected infants and children and in 6 of the 8 (all those tested) of the contacts of adult cases. The mother of case AS was found to be ay on 2 occasions, the
15 first time 2 months after delivery. Patient AS was found to be weakly positive for subtype y at 12 and 18 months of age and ay positive at 46 months, 6 months after the anti-HBs became undetectable. Case AA at 2 years after the beginning of vaccination, case AE 9 months after and both adult cases
20 (26 and 28 months after immunisation) were y positive only.

These results were confirmed using monoclonal reagents. All the cases with y-containing sera were neutralised with anti-y but not anti-a.

25

Subtyping of anti-HBs revealed that 50-70% of the antibodies were anti-a. In patient AS, at 6 months of age and thereafter, about 90% was against the a determinant.

30 (ii) Sequencing of the 'a' determinant

Patient AS was found by sequencing to have a single mutation from guanosine to adenosine (G to A) at position 587 (numbered from the unique Eco R1 site of the HBV genome),
35 resulting in an amino-acid substitution from glycine to

-17-

arginine at amino-acid 145 of HBsAg. This change was shown to be stable, as it was present both at the age of 11 months and at 5 years of age. The mother, IE, and the control patients had glycine at this point in the epitope, as in all 5 sequences published to date. The sequence of the a determinant was otherwise the same in patients AS and IE and the same as those previously published.

(iii) Hydrophobicity plots

10

The relative hydrophobicity of the second loop of the a determinant of normal HBsAg and that from patient AS was determined. Using the method of Kyte and Doolittle, J. Mol. Biol. 1982, 157, 105-132, the mean hydrophobicity index 15 for the second loop was found to have changed from -1.3 to -1.9, and from -0.5 to -0.9 using the method of Hopp and Woods (Proc. Natl. Acad. Sci. U.S.A., 1981, 78, 3824-3828).

Example 2

20

Contruction of a variant S-gene coding sequence of ay serotype containing a gly to arg replacement at amino acid position 145

25 Four oligonucleotide primers, BC17, BC144, BC145, and BC146, having the sequences shown below were synthesized by conventional phosphoramidite chemistry on a Biosearch 8600 DNA synthesizer according to the manufacturers instructions.

30 BC17 5' GTCTAGACTCGTGGTGGACT 3'
BC144 5' TTGGAATTCGTTAAATGTATA 3'
BC145 5' CTTCCGACAGAAATTGCACCT 3'
BC146 5' AGGTGCAATTCTGTCCGAAG 3'

-18-

These oligonucleotides have homology to the ay S-gene sequence on pRIT10601 as shown in Figure 3 and are used as primers for nucleotide extension by Taq polymerase with the ay S-gene as template. The underscored AGA and TCT triplets on BC145 and BC146 encode the desired arg145 substitution. Furthermore the sequence GAATTCG on BC144 enables introduction of an EcoRI restriction site one bp distal to the TAA termination codon of the S-gene coding sequence. The PCR reaction is carried out as specified by the manufacturer (Perkin Elmer Cetus) using either pRIT10601 or the plasmid pRIT13438 shown in Figure 4 as template. pRIT13438 is a conventional E. coli vector containing a complete ay S-gene coding sequence derived from pRIT10601 and flanked by EcoRI and BglIII restriction sites introduced by in vitro manipulation. About 1 to 10 ng of template DNA is mixed with 50 mM KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM MgCl₂, 0.01% (w/v) gelatin, 200 µM each of dATP, dGTP, dCTP, and dTTP, 1µM of each desired primer and 2.5 units of Taq polymerase in a final volume of 100 microlitres. Two separate reactions are set up, one containing BC17 and BC146 with the template, the other containing BC144 and BC145 with the template.

The two mixtures are subjected to 25 cycles of denaturation (2 min, 94°C), annealing (2 min, 48°C) and extension (2 min, 72°C) followed by one cycle with a 15 minute extension time at 72°C using a DNA Thermal Cycler (Perkin Elmer Cetus, obtained from Van der Heyden, Brussels, Belgium). The presence of the desired amplified fragment in each mixture is verified by conventional agarose gel electrophoresis and fragments are purified by passage over Centricon 100 columns (Amicon Division, W.R. Grace and Co, obtainable from Van der Heyden, Brussels, Belgium). About 1 to 10 ng of each amplified fragment is mixed in a single reaction with primers BC17 and BC144 and amplified exactly as described above except that the annealing reaction takes place at 60°C.

-19-

Additional oligonucleotide primers BC90 and BC153 having the sequences shown below may also be used in place of BC17 and BC144.

5 BC90 5' ATGGAGAACATCACATCAGCATTCTAGGA 3'
 BC153 5' TTGGAATTCGTTAAATGTATACCCAAAGACAAAA 3'.

BC90 has homology to the 5' end of the ay S-gene sequence starting at the initiation codon. BC153 overlaps BC144.

10

Two PCR reaction mixtures were set up, containing in one BC90 and BC146 together with pRIT13438 DNA as template and other ingredients as detailed above, and in the other BC145 and BC153 together with pRIT13438 as template and other
15 ingredients as detailed above. The two mixtures were then subjected to 25 cycles of denaturation (2 min. 94°C) anhealing (2 min., 48°C) and extension (2 min., 72°C) to permit amplification. The desired 445 bp fragment from the BC90/BC146 amplification and the 267 bp fragment from the
20 BC145/BC153 amplification were purified by polyacrylamide gel electrophoresis and electroelution.

About 10 ng of each fragment were then mixed and subjected to 25 cycles of PCR amplification in the presence of
25 oligonucleotides BC90 and BC153 in the same reaction conditions as described above. The resulting amplified fragment of about 690 bp was recovered and contains single recognition sites for XbaI and EcoRI endonucleases.

30 Use of these specific oligonucleotide primers, ay S-gene template and the PCR reaction results in the production of a variant 590 bp S-ay fragment having the arg145 substitution and 5' XbaI, 3' EcoRI extensions. The desired fragment is preferably purified from primers and other products of the
35 PCR reaction by passage over a Centricon 100 column. The fragment is then substituted by conventional cloning

-20-

techniques for the corresponding XbaI - EcoRI fragment of a normal viral coding sequence preferably fused to a yeast promoter. A vector suitable for this purpose is pNN2deltaEcoRI shown in Figure 5 where an ad serotype 5 coding sequence has been fused to the yeast TDH3 promoter and is upstream of the yeast ARG3 transcription terminator to form an expression cassette. The construction and use of such expression cassettes are taught in EP-A-0 278 940. It will be appreciated by one skilled in the art that any suitable vector of this type may be employed depending on the promoter and transcription terminator fragments selected to control expression in the yeast species chosen as host. Furthermore, other restriction sites could be introduced at the 3' end of the variant fragment by using primers other than BC144. It will be appreciated further that all nucleotide differences resulting in amino acid changes between known HBV isolates of adw and ayw serotypes reside downstream of the XbaI site so that substitution on pNN2deltaEcoRI of the variant XbaI - EcoRI fragment obtained by PCR results in an ayw coding sequence.

About 1.5 mcg of the 690 bp fragment resulting from the PCR reactions with BC90, BC153, BC145 and BC146 described above was digested with XbaI and EcoRI endonucleases and about 25 0.15 mcg of the digested fragment was mixed and ligated with about 50 ng of the vector pRIT12642 which had been digested with XbaI and EcoRI endonucleases and dephosphorylated. pRIT12642 is exactly identical to the pNN2deltaEcoRI vector shown in Figure 5. From the ligation mixture, a plasmid was recovered and identified as pRIT13555 which contains the XbaI-EcoRI fragment carrying the modified S-coding sequence inserted between the XbaI and EcoRI sites of the pRIT12642 vector, so as to form an expression cassette where the variant ay coding sequence is situated 3' to, and under the control of, the TDH3 promoter.

-21-

The resulting vHBsAg expression cassette obtained as described above is excised from the pNN2deltaEcoRI derivative plasmid as a 2.89 kb fragment by digestion with BglIII and SalI endonucleases and inserted on any vector of choice for introduction in yeast. A suitable multicopy vector for S. cerevisiae is pRIT12775 shown diagrammatically in Figure 6 which contains a polylinker inserted between the EcoRI and SalI sites on the pBR327 replicon and which was constructed by conventional DNA manipulation techniques using well known DNA fragments. The 2.98 BglIII-SalI cassette fragment from pRIT13555 was obtained by endonuclease digestion and inserted between the BglIII and SalI sites of pRIT12775 by conventional cloning techniques to form the plasmid pRIT13557. If it is desirable to integrate the cassette into the yeast genome an integrative vector such as those described in Jacobs et al, Gene, 80, page 279 (1989), is preferred. When proceeding with the insertion of the vHBsAg expression cassette on pRIT12775, yeast cells of a leucine2 deficient mutant are transformed by the method of Ito et al, J. Bacteriol. 153: p163 (1983) with selection for leucine independent transformants. A suitable recipient strain with a double leu2 mutation is strain DC5 deposited under the Budapest Treaty with the American Type Culture Collection on June 2, 1982 under accession number ATCC 20630.

A further suitable strain is a cir^0 derivative of DC5 which was deposited under the Budapest Treaty with the American Type Culture Collection on August 18, 1986 under accession number ATCC20820. Strain DC5 cir^0 was transformed with DNA of pRIT13557 by the method of Ito et al cited above with selection of leucine independent colonies. A transformant colony was retained and subcultured to establish the strain identified as Y1648.

35

An expression cassette carrying the vHBsAg coding sequence may also be transformed into host cells of S. cerevisiae, H.

-22-

polymorpha or P. pastoris which carry other expression cassettes so as to form composite HBsAg particles which contain a mixture of two or more polypeptide species.

5 Conventional cloning techniques were used to construct a 2.98 Kb expression cassette consisting of the yeast TDH3 promoter, the coding sequence of the S-gene of ay subtype from pRIT10601 and the yeast ARG3 terminator fragment. This cassette was then inserted between the BglII and SalI sites
10 of pRIT12775 to form pRIT13558. pRIT13558 was then introduced by transformation, using the technique of Ito et al cited above, into the recipient strain DC5 cir⁰ with selection for leucine independence. A transformant colony was retained and subcultured to establish the strain
15 identified as Y1654.

Strain Y1654 expresses HBsAg of ay subtype which is useful as a control when investigating the properties of the vHBsAg of the present invention.

20

Subcloning and expression of ay subtype particles in yeast using pRIT10601 as starting material and the yeast ARG3 promoter has been described by De Wilde et al in Devel. Biol. Standard. 59, 99-107 (1985).

25

Cultures of Y1648 and Y1654 were grown and the HBsAg extracted and measured in the crude cell extracts by AUSRIA radioimmunoassay (Abbott Laboratories, North Chicago, Illinois, U.S.A.). The results of assaying two cultures of
30 each of Y1648 and Y1654 are shown below.

-23-

5	STRAIN	CULTURE NUMBER	PROTEIN (g/l culture)	HBsAg by AUSRIA (g/l culture)	HBsAg as per cent protein
	Y1648	C1316	23.42	0.0115	0.049
		C1324	27.30	0.0131	0.05
10	Y1654	C1332	20.12	0.127	0.63
		C1336	26.09	0.136	0.52

15 Strain Y1648 produces about 10-fold less apparent AUSRIA reactive material compared to strain Y1654. Western blotting of crude cell extracts using monoclonal antibody HBS1 (SmithKline Beecham Biologicals, Rixensart, Belgium), recognizing the denatured and reduced HBV surface antigen
20 polypeptide, showed that Y1648 produced about the same amount of HBS1 reactive protein with a molecular weight of 24K as did Y1654.

Methods for the culture of yeast cells, extraction and assay
25 of HBsAg and Western blotting may be found in EP-A-0 278 940 and EP-A-0 414 374 both of which are incorporated herein by reference.

Surface antigen material was purified from cell extracts of
30 both Y1648 and Y1654 by conventional methods according to US Patents 4,649,192 and 4,683,294 cited above.

The preparations consisted of substantially pure HBV surface antigen protein as analyzed by SDS-PAGE and silver staining
35 which revealed single major bands of protein at 24K together with traces of dimers and multimers.

Two preparations of yeast derived HBsAg from strain Y1654 gave AUSRIA/protein ratios of 1.64 and 2.79 whereas two

-24-

vHBsAg preparations from strain Y1648 gave diminished
AUSRIA/protein ratios of 0.1 and 0.13.

Purified vHBsAg from strain Y1648 was examined by electron
microscopy after staining with uranyl acetate. The material
showed the presence of spherical particles typical for HBV
surface antigen.

Example 3

10

Preparation of a vaccine composition

To a sterile, buffered aqueous solution of 3% aluminium
hydroxide in 10 mM sodium phosphate, 150 mM NaCl, pH6.8, the
vHBsAg of Example 2 in similar buffer is added with constant
stirring to a final concentration of 5 to 40 mcg protein and
0.5 mg per ml of aluminium (Al^{3+}). Thimerosal (sodium
merthiolate) is then added to a 1 in 20,000 (w/v) final
concentration as preservative.

20

The vaccine is suitable for parenteral administration to
humans.

-25-

Claims

1. A hepatitis B surface antigen protein or fragment thereof displaying the antigenicity of HBV surface antigen, 5 characterised in that the said protein or fragment thereof (vHBsAg) comprises a modified 'a' determinant in which there is an amino acid other than glycine at position 145 of the HBsAg sequence.
- 10 2. A vHBsAg as claimed in claim 1 in which the glycine residue at position 145 is replaced by a more hydrophilic amino acid.
3. A vHBsAg as claimed in claim 1 or claim 2 in which the 15 amino acid at position 145 can be derived by a point mutation in the GGA codon coding for glycine at position 145 in normal HBsAg.
4. A vHBsAg as claimed in any one of claims 1 to 3 which 20 is identical to normal HBsAg S-protein except for the altered amino acid residue at position 145.
5. A vHBsAg as claimed in any one of claims 1 to 4 in which the modification at position 145 is substitution of 25 glycine by arginine.
6. A vHBsAg as claimed in any one of claims 1 to 5 which is greater than 75% pure.
- 30 7. An expression vector comprising a DNA sequence encoding a vHBsAg according to any one of claims 1 to 5.
8. A host transformed with the vector of claim 7.

-26-

9. A vaccine composition comprising an effective amount of a vHBsAg as claimed in claim 6, admixed with a suitable carrier or adjuvant.

5 10. A process for preparing a vHBsAg as claimed in any one of claims 1 to 6, which process comprises the steps of culturing a host according to claim 8 in an appropriate culture medium, and purifying the vHBsAg produced to the required degree of purity.

10

11. The use of a vHBsAg according to any one of claims 1 to 6 in the manufacture of a vaccine for protecting a human against disease associated with HBV.

15 12. A kit for diagnostic in vitro detection of anti-vHBsAg antibodies in a biological medium, characterised in that the kit comprises:

(a) vHBsAg according to any one claims 1 to 6; and

20 (b) means adapted to detect the antigen-antibody reaction.

13. An antibody preparation comprising anti-vHBsAg antibodies for use in the prevention or treatment of hepatitis B infection in humans.

25

1 / 3




Fig.1




Fig.2

2 / 3




Fig. 3




Fig. 4

3 / 3




Fig.5




Fig.6

INTERNATIONAL SEARCH REPORT

PCT/GB 91/00444

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC C 07 K 13/00, IPC ⁵ : C 12 N 15/51, A 61 K 39/29, G 01 N 33/576, A 61 K 39/395		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC ⁵	C 12 N, C 07 K, A 61 K, G 01 N	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	Molecular Immunology, volume 26, no. 2, 1989, Pergamon Press Plc., (GB), Hiroaki Okamoto et al.: "The loss of subtypic determinants in alleles d/y or w/r, on hepatitis B surface antigen", pages 197-205 see table 2 <div style="text-align: center;">--</div>	1,3,4,6-10
A	Journal of Medical Virology, volume 29, 1989, Alan R. Liss, Inc., P.G. Ashton-Rickardt et al.: "Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodomi- nant a region", pages 196-203 <div style="text-align: center;">--</div> <div style="text-align: center;">./.</div>	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search <div style="text-align: center;">2nd July 1991</div>	Date of Mailing of this International Search Report <div style="text-align: center;">13. 08. 91</div>	
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorised Officer 	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	<p>The Lancet, volume 336, 11 August 1990, W.F. Carman et al.: "Vaccine-induced escape mutant of hepatitis B virus", pages 325-329 see the whole document</p> <p>-----</p>	1-13